ArticleAddictive behaviors reports2026
Exploring the effects of cannabidiol on pain sensitivity using quantitative sensory testing among individuals receiving methadone or buprenorphine for opioid use disorder: an open-label, proof-of-concept study.
Article in Addictive behaviors reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- An opioid-withholding human laboratory paradigm during opioid agonist treatment for opioid use disorder and chronic pain: Phase- and dose-dependent effects of cannabidiol.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Trial
- Brief Report: Is once daily enough? Assessing the impact of timing of methadone dose on pain sensitivity via quantitative sensory testing in persons with opioid use disorder.The American journal on addictions · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While medications for opioid use disorder (MOUD) effectively treat opioid use disorder (OUD), concurrent pain management remains challenging. Cannabidiol (CBD) shows promise in both pain management and OUD treatment. This open-label, proof-of-concept study aimed to evaluate the safety and tolerability of cannabidiol (CBD) and explore its utility for pain sensitivity using quantitative sensory testing (QST) among individuals with co-occurring OUD and chronic pain. Seven individuals with OUD receiving methadone or buprenorphine and experiencing chronic pain completed three test sessions with ascending oral CBD doses (400 mg, 800 mg, 1200 mg). QST analyses for pain sensitivity showed no significant main effects of CBD dose or time but revealed a significant MOUD x CBD dose interaction for heat pain threshold and tolerance. Post-hoc comparisons indicated that participants receiving buprenorphine exhibited significantly higher heat threshold (400 mg) and heat tolerance (800 mg) compared to those receiving methadone. Descriptively, the 400 mg CBD dose was associated with the most favorable pain response patterns across several QST measures in the buprenorphine group. CBD was well-tolerated across all doses; no serious adverse events, changes in subjective effects, or adverse cognitive effects on verbal memory were reported. In conclusion, this pilot study offers preliminary indications that CBD's impact on pain sensitivity varies by dose and MOUD type, notably with potential benefits at 400 mg for individuals on buprenorphine. Coupled with its demonstrated safety and tolerability, these findings support future larger, placebo-controlled randomized trials to confirm CBD's therapeutic utility for pain in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.